Not So Different: Julie Kennerly-Shah, PharmD, on How Biosimilars Can Help Curb COVID-19's Impact

September 27, 2020


We sat down with Julie Kennerly-Shah, PharmD, assistant director of Pharmacy at the Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute to discuss cost cutting with biosimilars.

Not So Different: Rep Grothman on His Bill to Make Biosimilar Insulins Interchangeable

September 20, 2020


We sat down with Representative Glenn Grothman (R-Wisconsin), the author of HR 8190, a bill that would waive interchangeability requirements for biosimilar insulins, to discuss why this bill is needed for Americans and what it could mean for future biosimilar legislation.

Not So Different: Alex Moulson on How Companies Choose Which Biosimilars to Produce

September 13, 2020


We sat down with Alexandra Moulson, vice president of Strategy, Programs, and Portfolio at Polpharma Biologics to discuss how Polpharma Biologics and other contract development and manufacturing organization (CDMOs) function and how companies choose which molecules to develop.

Cheryl Larson on How Employers Can Get Biosimilars Added to Their Health Plan

September 6, 2020


We sat down with Cheryl Larson, president and CEO of Midwest Business Group on Health (MBGH), an employer coalition based in Chicago, Illinois, to discuss the current obstacles employers face in getting biosimilars added to their formularies and what steps they can take to get around them.

Jonathan Sweeting on Aybintio's European Approval

August 30, 2020


We sat down with Jonathan Sweeting, head of Samsung Bioepis’ European business, to discuss the steps leading up to the European approval of Aybintio and what the current bevacizumab market in Europe looks like.

Nancy Globus, PharmD, on the Effect of Biosimilar Suffixes

August 23, 2020


We sat down with Nancy Globus, PharmD, vice president of Regulatory Affairs at the Accreditation Council for Medical Affairs (ACMA), to discuss the true impact that suffixes have on biosimilar perception and whether they are appropriate for the United States.

Carter Thorne, MD, Discusses Biosimilar Switching in Canada

August 16, 2020


We sat down with Carter Thorne, MD, FRCPC, former president of the Canadian Rheumatology Association and chief of the Division of Rheumatology and director of The Arthritis Program at Southlake Regional Health Centre in Newmarket, Ontario, to discuss the current status of Canada’s comfort level with biosimilars and what he sees for the future of switching policies.

Sizing Up European Biosimilar Competition

August 9, 2020


We sat down with Adrian van den Hoven, director general of Medicines for Europe, and Diogo Piedade, market access manager for Medicines for Europe, to discuss their scorecard report for biosimilar access and what European markets they feel need the most work.

Dorothy McCabe, PhD, Discusses How to Combat Biosimilar Misinformation

August 2, 2020


We sat down with Dorothy McCabe, PhD, the executive director of clinical development and medical affairs, immunology and biosimilars at Boehringer Ingelheim Pharmaceuticals and co-chair of the Biosimilars Forum education committee, to discuss what more needs to be done to combat biosimilar misinformation and how patients and physicians can help the cause.

Rathore: What Biosimilar Developers Can Learn From Application Failures

July 26, 2020


We sat down with Anurag Rathore, PhD, lead author of the study and coordinator of the Center of Excellence for Biopharmaceutical Technology in Delhi, India, to discuss the findings from this study and how biosimilar corporations can learn from them.